MYRIAD GENETICS INC (MYGN)       19.94  +0.22 (+1.12%)

19.94  +0.22 (+1.12%)

US62855J1043 - Common Stock - After market: 19.6 -0.34 (-1.71%)

Buy % Consensus

47
Analysts have set a mean price target of 19.25. This target is -3.45% below the current price.
MYGN was analyzed by 14 analysts. The buy percentage consensus is at 47. So analysts seem to be rather neutral about MYGN.
In the previous month the buy percentage consensus was at a similar level.
MYGN was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target

Price Low Median Mean High 19.9413.1319.3819.2526.25 - -34.15% -2.81% -3.45% 31.64%

Up and Down Grades

Date Firm Action Rating
2023-01-18 Raymond James Upgrade Market Perform -> Outperform
2022-11-02 SVB Leerink Maintains Market Perform
2022-10-06 Stephens & Co. Initiate Equal-Weight
2022-08-05 SVB Leerink Maintains Market Perform
2022-05-05 SVB Leerink Maintains Market Perform
2022-04-19 Goldman Sachs Maintains Sell
2021-11-03 SVB Leerink Maintains Market Perform
2021-06-15 Raymond James Initiate Market Perform
2021-06-03 Goldman Sachs Initiate Sell
2021-02-24 SVB Leerink Maintains Market Perform

Analyst Ratings Stock Screener Links

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA